Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tyra Biosciences SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company developing FGFR-focused precision medicines. Recent 8-K reports cover operating results, clinical-program updates for TYRA-300/dabogratinib, officer and board appointments, and capital actions under a registered at-the-market offering program.
Proxy materials describe annual meeting voting matters, board structure and corporate-governance procedures. Registration-linked disclosures and material-event reports also identify TYRA common stock, equity issuance activity, and the company’s use of SEC exhibits for press releases and other official corporate records.
Tyra Biosciences, Inc. (TYRA) – Form 4 insider transaction
Director Gilla Kaplan filed a Form 4 disclosing two open-market sales of the company’s common stock.
- 06/17/2025: Sold 10 shares at $10.35 each.
- 06/18/2025: Sold 9,568 shares at a $9.7822 weighted-average price (individual trades ranged from $9.55 to $9.93).
After these transactions, Kaplan’s direct beneficial ownership stands at 28,231 shares. No derivative securities were involved, and the filing does not reference any 10b5-1 trading plan. The document was signed by Attorney-in-Fact Ali D. Fawaz on 06/20/2025.